Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.7071 -0.0922 (-11.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,423,834
Open 0.7170
Bid (Size) 0.7071 (16)
Ask (Size) 0.7400 (2)
Prev. Close 0.7993
Today's Range 0.6800 - 0.7671
52wk Range 0.3546 - 2.740
Shares Outstanding 109,755,624
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Invivyd Revenue Jumps 413 Percent in Q2
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga

Performance

YTD
+47.3%
+47.3%
1 Month
+2.9%
+2.9%
3 Month
-9.0%
-9.0%
6 Month
-56.1%
-56.1%
1 Year
-32.0%
-32.0%

More News

Read More
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
From Invivyd
Via GlobeNewswire
What to Expect from Invivyd's Earnings
Via Benzinga
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
From Invivyd
Via GlobeNewswire
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
From Invivyd
Via GlobeNewswire
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
From Invivyd
Via GlobeNewswire
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Earnings Scheduled For May 15, 2025
Via Benzinga
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
From Invivyd
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
From Invivyd
Via GlobeNewswire
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
From Invivyd
Via GlobeNewswire
Wednesday's session: top gainers and losers
Via Chartmill
What's Going On With Invivyd Stock On Monday?
Via Benzinga

Frequently Asked Questions

Is Invivyd, Inc. - Common Stock publicly traded?
Yes, Invivyd, Inc. - Common Stock is publicly traded.
What exchange does Invivyd, Inc. - Common Stock trade on?
Invivyd, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Invivyd, Inc. - Common Stock?
The ticker symbol for Invivyd, Inc. - Common Stock is IVVD on the Nasdaq Stock Market
What is the current price of Invivyd, Inc. - Common Stock?
The current price of Invivyd, Inc. - Common Stock is 0.7071
When was Invivyd, Inc. - Common Stock last traded?
The last trade of Invivyd, Inc. - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of Invivyd, Inc. - Common Stock?
The market capitalization of Invivyd, Inc. - Common Stock is 77.61M
How many shares of Invivyd, Inc. - Common Stock are outstanding?
Invivyd, Inc. - Common Stock has 78M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.